CONGESTIVE HEART FAILURE (CHF) PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://congestiveheartfailure.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. In acute HF treatment, which statement about vasodilatory therapy is listed?

A. Hospitalization

B. IV diuresis

C. Nesiritide recombinant human BNP

D. Nitrates and vasodilation

2. Which therapy may have better efficacy than an ACE inhibitor or an ARB in heart failure?

A. ARNi

B. ACE inhibitors

C. ARBs

D. SGLT2 inhibitors

3. Stage C HF is defined as ...

A. No symptoms but decreased EF

B. Refractory HF at rest

C. At risk but no symptoms

D. Structural heart disease with HF symptoms

4. On physical examination, which combination of findings suggests fluid overload in heart failure?

A. S3 heart sound with elevated JVP

B. S4 gallop with no edema

C. Murmur of aortic stenosis

D. Clear lungs without edema

5. Hyponatremia in decompensated heart failure is primarily due to which mechanism?

A. Hyperkalemia due to aldosterone

B. Hypernatremia due to dehydration

C. Hyponatremia due to neurohormonal activation and water retention

D. Hypocalcemia due to PTH

SAMPLE

6. Which heart failure phenotype is generally associated with the worst prognosis?

A. HFpEF

B. HFmrEF

C. HFrEF

D. All subtypes have identical prognosis

7. What is the main purpose of using natriuretic peptides beyond diagnosis?

A. Prognostication and guiding therapy intensity; trending levels help gauge response

B. Predicting arrhythmias with precision

C. Directly measuring renal function

D. Determining the cause of chest pain

8. What is a common and appropriate approach to edema in HFpEF?

A. Increase salt intake

B. Diuretics to address edema

C. No therapy for edema

D. Remove diuretics

9. Neurohormonal blockade includes which of the following classes?

A. Beta blockers

B. ACE inhibitors

C. MRAs

D. All of the above

10. Stage A HF is defined as ...

A. Structural heart disease with HF symptoms

B. At risk but no symptoms (hypertension, coronary artery disease, diabetes, family history)

C. No symptoms but decreased EF & signs of structural disease

D. Refractory HF symptoms at rest despite therapy

SAMPLE

Answers

SAMPLE

1. D
2. A
3. D
4. A
5. C
6. C
7. A
8. D
9. D
10. B

SAMPLE

Explanations

SAMPLE

1. In acute HF treatment, which statement about vasodilatory therapy is listed?

A. Hospitalization

B. IV diuresis

C. Nesiritide recombinant human BNP

D. Nitrates and vasodilation

Vasodilators in acute heart failure work by lowering both preload and afterload, which unloads the failing heart, reduces pulmonary congestion, and can improve forward blood flow. Nitrates provide rapid venodilation, lowering LV filling pressures and, at higher doses, afterload as well. This quick reduction in filling pressures directly relieves dyspnea and pulmonary edema and is a central, practical approach when the patient's blood pressure can tolerate the drop. The other options aren't vasodilator therapies: hospitalization is a setting, IV diuresis targets fluid overload rather than vasodilation, and while nesiritide is a vasodilator, nitrates are the classic, commonly used vasodilator in acute decompensation.

2. Which therapy may have better efficacy than an ACE inhibitor or an ARB in heart failure?

A. ARNi

B. ACE inhibitors

C. ARBs

D. SGLT2 inhibitors

The main idea is that combining neprilysin inhibition with angiotensin receptor blockade provides superior outcomes in heart failure with reduced ejection fraction compared with an ACE inhibitor or an ARB alone. Neprilysin normally breaks down natriuretic peptides, so inhibiting it increases these beneficial peptides, promoting vasodilation, natriuresis, and anti-remodeling effects. Coupling this with an ARB blocks the harmful angiotensin II effects, giving a dual attack on the neurohormonal pathways that drive heart failure progression. In the pivotal PARADIGM-HF trial, sacubitril/valsartan reduced cardiovascular death and heart failure hospitalization more than enalapril in symptomatic HFrEF, establishing its superior efficacy over a traditional ACE inhibitor. That's why guidelines favor switching eligible patients from an ACE inhibitor or ARB to this ARNi. When switching from an ACE inhibitor to an ARNi, a washout period is recommended to reduce angioedema risk. SGLT2 inhibitors also improve heart failure outcomes, but the strongest evidence showing superiority over an ACE inhibitor or ARB specifically points to this combination therapy.

SAMPLE

3. Stage C HF is defined as ...

A. No symptoms but decreased EF

B. Refractory HF at rest

C. At risk but no symptoms

D. Structural heart disease with HF symptoms

The concept being tested is how the ACC/AHA stages of heart failure are defined. Stage C is characterized by structural heart disease with current or prior HF symptoms, meaning you have clear signs or symptoms of heart failure while there is an underlying heart abnormality. Structural heart disease can include previous myocardial infarction with remodeling, valve disease, cardiomyopathy, or other conditions that alter heart structure. The symptoms that accompany it are the typical HF manifestations—shortness of breath, fatigue, reduced exercise tolerance, and sometimes edema. Why the other descriptions don't fit Stage C: having no symptoms despite reduced left ventricular ejection fraction places you in Stage B (structural disease without symptoms). Refractory HF at rest describes a very advanced stage, i.e., Stage D, where symptoms persist despite optimal therapy. Being at risk but asymptomatic corresponds to Stage A, where there's risk but no structural heart disease or symptoms yet. So, Stage C = structural heart disease with HF symptoms.

4. On physical examination, which combination of findings suggests fluid overload in heart failure?

A. S3 heart sound with elevated JVP

B. S4 gallop with no edema

C. Murmur of aortic stenosis

D. Clear lungs without edema

Fluid overload from heart failure raises filling pressures and causes systemic venous congestion. An S3 heart sound is the extra beat that happens with rapid ventricular filling into a dilated, failing ventricle and reflects increased volume and reduced ventricular compliance. Elevated JVP shows high right-sided filling pressures and venous congestion. Together, these findings point to excess fluid in the circulation and congested heart failure, which is the essence of fluid overload. The other patterns don't fit as well. An S4 gallop indicates a stiff, noncompliant ventricle and is more about diastolic dysfunction than acute volume overload. A murmur of aortic stenosis points to a structural valve issue rather than fluid status. Clear lungs without edema suggests there isn't pulmonary edema at that moment.

5. Hyponatremia in decompensated heart failure is primarily due to which mechanism?

A. Hyperkalemia due to aldosterone

B. Hypernatremia due to dehydration

C. Hyponatremia due to neurohormonal activation and water retention

D. Hypocalcemia due to PTH

In decompensated heart failure, hyponatremia mainly comes from dilutional water retention driven by neurohormonal activation. When the heart's pumping ability drops, the effective circulating volume falls, and the body kicks in with systems that conserve both sodium and water to preserve perfusion: the renin-angiotensin-aldosterone system, increased sympathetic activity, and especially antidiuretic hormone (vasopressin) release. Vasopressin acts on the kidneys to reabsorb free water in the collecting ducts. This water retention outpaces sodium retention, so the serum sodium concentration drops even though total body sodium and water may be high. The result is hyponatremia. The other options don't fit this mechanism: aldosterone-driven potassium effects don't cause hyponatremia, dehydration would raise sodium (hypernatremia), and PTH-related calcium changes are unrelated to acute sodium balance.

SAMPLE

6. Which heart failure phenotype is generally associated with the worst prognosis?

A. HFpEF

B. HFmrEF

C. HFrEF

D. All subtypes have identical prognosis

The key idea is that prognosis in heart failure varies by the type of heart failure, and the reduced ejection fraction type is the one most consistently linked to worse outcomes. When the left ventricle's pumping ability is markedly diminished (ejection fraction well below normal), forward flow to the body is severely limited, leading to ongoing organ hypoperfusion, progressive ventricular remodeling, higher susceptibility to dangerous rhythms, and more frequent hospitalizations. These factors translate into higher mortality risk compared with the preserved-ejection fraction form, where patients often have substantial symptoms but, on average, better survival, though they still carry significant risk due to comorbidities. The mid-range category generally falls between the two in prognosis. So the heart failure phenotype with the worst prognosis is the reduced-ejection-fraction type.

7. What is the main purpose of using natriuretic peptides beyond diagnosis?

A. Prognostication and guiding therapy intensity; trending levels help gauge response

B. Predicting arrhythmias with precision

C. Directly measuring renal function

D. Determining the cause of chest pain

Natriuretic peptides rise with cardiac wall stress, and their value goes beyond confirming that heart failure is present. They are powerful for prognosis and for guiding how aggressively to treat. Higher levels signal greater risk of adverse outcomes, so they help clinicians stratify patients and tailor therapy intensity. Serial measurements—watching how the levels trend over time—tell you how well treatment is working. If the levels fall with diuresis and optimization of guideline-directed medical therapy, that supports decongestion and improvement; if they stay elevated or rise, it suggests persistent congestion or worsening disease and may prompt adjustments in therapy or closer follow-up. Other options don't fit as the main purpose. They don't provide precise predictions for arrhythmias, nor do they directly measure renal function, and they aren't used to determine the cause of chest pain.

8. What is a common and appropriate approach to edema in HFpEF?

A. Increase salt intake

B. Diuretics to address edema

C. No therapy for edema

D. Remove diuretics

In HFpEF, edema comes from elevated filling pressures due to a stiff ventricle, so relieving fluid overload is the main therapy for symptoms. Diuretics are the cornerstone because they reduce preload and venous congestion, which directly improves edema and related symptoms like shortness of breath and leg swelling. Loop diuretics are commonly used and dosed to achieve euvolemia, guided by weight, edema, and symptoms, while monitoring for dehydration, kidney function, and electrolyte balance. Increasing salt intake would worsen edema, no therapy leaves edema unresolved, and removing diuretics would allow fluid overload to return. So diuretics to address edema is the best approach.

EXAMPLE

9. Neurohormonal blockade includes which of the following classes?

A. Beta blockers

B. ACE inhibitors

C. MRAs

D. All of the above

Neurohormonal blockade targets the maladaptive activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system that drives progression in heart failure. Beta blockers blunt chronic sympathetic stimulation, lowering heart rate and myocardial oxygen demand and reducing renin release. ACE inhibitors block the formation of angiotensin II, leading to vasodilation, reduced aldosterone-mediated fluid retention, and favorable remodeling. Mineralocorticoid receptor antagonists directly block aldosterone's effects, providing additional diuretic and antifibrotic benefits. Because each therapy tackles a different part of the same harmful neurohormonal cascade, all three are considered neurohormonal blockade. So the best answer is that all of these classes are included. In practice, these are used together when appropriate, with monitoring for side effects like hyperkalemia or kidney function changes with MRAs and ACE inhibitors, and careful titration of beta blockers.

10. Stage A HF is defined as ...

A. Structural heart disease with HF symptoms

B. At risk but no symptoms (hypertension, coronary artery disease, diabetes, family history)

C. No symptoms but decreased EF & signs of structural disease

D. Refractory HF symptoms at rest despite therapy

Stage A heart failure is about being at high risk for developing heart failure without having any structural heart disease or symptoms yet. It includes people who have risk factors such as high blood pressure, coronary artery disease, diabetes, or a family history of heart disease, but there are no signs or symptoms of HF and no detectable structural changes. The goal at this stage is prevention: aggressively manage risk factors, optimize blood pressure and metabolic health, and monitor for any signs that heart structure or function is changing. Other descriptions reflect different stages: having structural heart disease with symptoms points to a later stage where HF symptoms are present; having no symptoms but visible structural changes like reduced ejection fraction fits a stage where structural disease exists without symptoms; and persistent symptoms despite therapy at rest denotes a more advanced stage requiring specialized intervention.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://congestiveheartfailure.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE